Sector News

Novartis invests $250m in malaria elimination commitment

June 24, 2022
Life sciences

Novartis has endorsed the ‘Kigali Declaration’ on neglected tropical diseases (NTDs) by announcing a five-year financial commitment of $250m.

The Kigali Summit on Malaria and NTDs is currently running alongside the 26th Commonwealth Heads of Government (CHOGM) meeting.

Novartis’ investment prioritises malaria – a disease it has been focussed on eliminating for many years. It also includes a $100m investment to advance the research and development of its neglected tropical disease programme, concentrating on novel drug candidates for four diseases.

In partnership with Wellcome, the Novartis Institute for Tropical Diseases is working to discover novel anti-parasitic therapies for Chagas disease. Furthermore, the company is collaborating with the Drugs for Neglected Diseases Initiative to jointly develop LXE408 for the treatment of visceral leishmaniasis. It will also be developing therapies for dengue fever and parasitic diarrhoea – major causes of mortality among young children in developing countries.

“Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done. Novartis will continue progressing our longstanding commitment to helping realise a world free of NTDs,” explained Vas Narasimhan, CEO of Novartis. “Today, by endorsing the Kigali Declaration and pledging to invest $250m, we aim to accelerate progress toward elimination of these diseases, which continue to cause suffering and stigma for millions of people around the globe.”

Novartis was among the original endorsers of the London Declaration on NTDs in 2012, committing to a multidrug therapy donation to support global efforts to eliminate leprosy. This was followed with a further commitment of $100m toward the fight against malaria in 2018.

Around the world, 1.7 billion people suffer from NTDs, which are prevalent in tropical areas and mostly affect impoverished communities, causing devastating health, social and economic consequences.

By John Pinching

Source: pharmatimes.com

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach